Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. - Wikidata - wikimedia - TriplyDB

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q35207110

about

The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer Caffeic acid phenethyl ester causes p21 induction, Akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells.Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2.Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells.Caffeic Acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signaling Cholestane-3β, 5α, 6β-triol suppresses proliferation, migration, and invasion of human prostate cancer cells Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway.A walnut-enriched diet reduces the growth of LNCaP human prostate cancer xenografts in nude mice Testosterone therapy and prostate cancer.Friend or foe: role of E-cadherin in prostate cancer metastasis.Quality of Life and Sexual Health in the Aging of PCa Survivors.Pomegranate and its components as alternative treatment for prostate cancer.Testosterone Therapy Among Prostate Cancer Survivors.Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro.The prostate cancer-up-regulated Myc-associated zinc-finger protein (MAZ) modulates proliferation and metastasis through reciprocal regulation of androgen receptor.Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis.Prognostic relevance of androgen receptor expression in renal cell carcinomas.Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.Involvement of Bax and Bcl-2 in Induction of Apoptosis by Essential Oils of Three Lebanese Salvia Species in Human Prostate Cancer Cells.Synthesis and evaluation of naphthalene-based thiosemicarbazone derivatives as new anticancer agents against LNCaP prostate cancer cells.Androgen receptor signaling regulates T-type Ca2+ channel expression and neuroendocrine differentiation in prostate cancer cells.Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer.Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer.Q57133498

P2860

Q26738703-E0573038-4BF9-4A6A-9C9D-8D176F11984E Q26774902-682DA812-150C-4CA4-B013-C8B098D5C6D7 Q34162761-20AF9B64-01D8-4E25-9567-203F96C803EE Q34278855-42EE7EFD-13C6-4056-B38C-F3B8F61EB890 Q35070404-284344C5-7E9E-4785-97C6-337537F2B6AD Q35740051-70857A74-1C6C-4D01-86E8-4B00BAB8B342 Q36389442-504E22B6-43C7-4DC7-9410-45BE621ECCD2 Q36790229-3A9969E6-8AE9-4C85-A434-7B54B3F99EDB Q36926791-0E877055-3374-4F4F-95D6-0D7A37E9BA8A Q36959063-88C732D9-EBD3-472F-9823-2D5D6D27A498 Q37007714-E0B6AAE1-95ED-4E4D-86DB-F1E0A8ED8715 Q37531045-41C74CAD-CA01-47C2-80F7-4B0BE8E99E56 Q37531067-04E9693E-E5FF-43BC-9111-5D13FDE54940 Q37686901-4EC6FF24-4012-4FBE-BFDD-2B761C9D78D6 Q38243393-3941FBC0-6741-4CE9-A361-9E5304846A4F Q38913362-C0615BC4-A7E5-4F98-94DF-FAAEBFFB8202 Q38985492-23D4A723-2CFF-4C5B-9C76-6C71783ECFC5 Q39162205-15635A8C-9704-4710-A030-7D604E89A483 Q42170228-FD15C629-9401-4896-B9FA-2B3922F958ED Q47131818-D254E4C7-CE4E-4C5C-9043-8B024CA53DA5 Q47359141-86B51BC3-C94C-4DB0-86B2-D20E0E9B95DC Q47805050-15D14A87-B5F3-4BE8-B01E-D21A68A89F6D Q47825566-A66D0B28-D896-400B-BDED-BD632CDB2358 Q48207681-9D0E4A29-1567-4EFA-B77E-B6BA7DB41FA8 Q53563179-417D1819-CFD5-478E-A809-415A57A48E34 Q53686355-02BBD0A8-D117-4AC8-9FB4-1C947367E903 Q55096243-64348E34-618E-4D17-AF6A-7F9E9423D6B1 Q55112139-BF09AF6B-4F7C-4B7A-A7F0-D9CC3E34ED9B Q57133498-492C5339-35A7-43BB-87C7-D976E7016BD2

P2860

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q35207110

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

@ast

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

@en

type

label

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

@ast

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

@en

prefLabel

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

@ast

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

@en

P1433

Q35207110-D17A27E6-78FA-4400-9C63-3B9C461F1424

P1476

Q35207110-553812B7-C8B7-4E08-A9A9-C05BB65717AE

P2093

Q35207110-0BBAF381-1D16-4293-AA97-B98DCE5A7AC1

Q35207110-0F1AF856-8753-4C86-9B44-09596583CDEB

Q35207110-2B667864-3DE4-4E43-9AEB-3BC4C8595D51

Q35207110-4A1A03E6-3CF0-46C0-A682-1DAB45AD7A31

Q35207110-66C8B425-A555-419D-9090-8735314929CF

Q35207110-967527CB-C94D-44FA-99F8-74A8C7209DC8

Q35207110-CD3974CF-89A6-40FF-A1B4-7CB3EE627321

Q35207110-D59363E3-EA50-47B0-8165-D7BE990833BE

P275

Q35207110-84376C46-9202-4A99-82E3-D2C5E96947BD

P2860

Q35207110-00A4B97D-FA83-4E56-99B9-A4C9E7B20325

Q35207110-04AE25EF-4F40-4807-BC0F-4C9691954C37

Q35207110-0812EC31-F395-46D2-8DC7-6C41193C8278

Q35207110-0A851D81-200D-4174-B4CC-B700E24D1B0B

Q35207110-0E8C658A-E0F4-4E6F-BAFC-E2C132049F28

Q35207110-0F332B5C-96E2-4B18-BA02-FEBE7EACC4C0

Q35207110-1227A464-CDC4-473A-B87B-F5DC6D2116E5

Q35207110-1C8B5D92-FA54-44EC-A2F0-95A3B1F4FC19

Q35207110-1F76CA84-E861-473E-A3E9-546F928F4FD0

Q35207110-212976A5-F19A-4B1D-9EF1-B20C6A44A82C

P2888

Q35207110-7C1DEB26-3593-4618-BB36-FEF9E7B1106D

P304

Q35207110-6A3085BE-1C84-41C8-9B45-510B7D6561B8

P31

Q35207110-78CDEBFA-48F9-475E-A798-CC64529ADE0B

Q35207110-D8A1BE98-862B-4CB7-B5C7-B6BE667D7C49

P356

Q35207110-6D24E48B-A2F5-4784-9F25-5000AFE523F0

P478

Q35207110-17E75831-EF45-4E49-B340-BDC1AB79B7A7

P5008

Q35207110-21EB29D5-3550-4DD0-94DF-466F3F42177E

P577

Q35207110-57BAC6D8-2B21-4A73-91B4-9CA3DF69849E

P5875

Q35207110-71EADC7B-C640-48BB-9E63-A8D217A258A7

P6179

Q35207110-3B2A3BE4-97F6-4C50-9D00-C3B932B800B6

P698

Q35207110-BC129047-05FE-4868-BAD6-FF78C6931D0A

P921

Q35207110-04500F00-8BFB-4E13-A04F-04A92207291F

Q35207110-3167913F-1BA1-46D7-8ADB-00104D47D9AE

Q35207110-5635C2CD-49C8-4EBF-9D28-571B18DBA888

Q35207110-8AA939A2-4AB2-440A-ACCF-550E2A3B7B17

Q35207110-8B80B0D6-0ABB-487D-B35C-487BEA5BB7AE

Q35207110-E9DA180B-840F-4BC8-820A-AA1EC67546DC

P932

Q35207110-69AAF4CC-96F4-4D53-AD5B-B4C5338DCD40

P356

1423-0127-18-63

P1433

Journal of Biomedical Science

P1476

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

@en

P2093

Chiech Huo

http://www.w3.org/2001/XMLSchema#string

Chih-Pin Chuu

http://www.w3.org/2001/XMLSchema#string

Ching-Yu Lin

http://www.w3.org/2001/XMLSchema#string

Hui-Ping Lin

http://www.w3.org/2001/XMLSchema#string

John M Kokontis

http://www.w3.org/2001/XMLSchema#string

Junichi Fukuchi

http://www.w3.org/2001/XMLSchema#string

Liang-Cheng Su

http://www.w3.org/2001/XMLSchema#string

Richard A Hiipakka

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride

The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells.

p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27

SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27

Molecular determinants of resistance to antiandrogen therapy

Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist

Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation

Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells

Modulation of liver X receptor signaling as novel therapy for prostate cancer

The development of androgen-independent prostate cancer

P2888

1423-0127-18-63

P304

63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1423-0127-18-63

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2011-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51588253

http://www.w3.org/2001/XMLSchema#string

P6179

1011729187

http://www.w3.org/2001/XMLSchema#string

P698

21859492

http://www.w3.org/2001/XMLSchema#string

P921

intracellular receptor

prostate cancer

regulation of gene expression

polycyclic compound

physiological phenomena

P932

3170584

http://www.w3.org/2001/XMLSchema#string